Clinical Trials Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Total 393 results

Shanghai Pharmaceuticals Holding Co., Ltd

Active, not recruiting

Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients

Chronic Abnormal Immune Activation in HIV/AIDS

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma

CD20 Positive B Cell Non-Hodgkin's Lymphoma

China
Shanghai Pharmaceuticals Holding Co., Ltd

Withdrawn

Phase I Study of SPH1188-11 in NSCLC (SPH1188-11)

NSCLC Stage IV | NSCLC Stage IIIB

China
Shanghai Acebright Pharmaceuticals Co., Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics of Simmiparib in Patients With Malignant Advanced Solid Tumor

Malignant Advanced Solid Tumor

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis

Ankylosing Spondylitis

China
Shanghai Pharmaceuticals Holding Co., Ltd

Not yet recruiting

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Biliary Tract or Colorectal Cancer With Her2-positive/Mutated

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Clinical Study of T3011 in Subjects With Advanced Melanoma

Advanced Melanoma

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Breast Cancer Brain Metastases

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Locally Advanced or Metastatic Breast Cancer

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

Mild to Moderate Ulcerative Colitis

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Acute Ischemic Stroke

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Diabetic Kidney Disease

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

HER2-positive Advanced Solid Tumors

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

Sarcoma, Ewing

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

A Food Effect Study of SPH5030 Tablets.

Advanced Solid Tumor

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

B002 in Patients With HER2-positive Breast Cancer (B002-101)

Metastatic Breast Cancer | Recurrent Breast Cancer

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Study on Human Mass Balance of SPH3127 Tablets

Primary Mild and Moderate Hypertension

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers

Hypertension

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

Hypertension

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

The Effect of Food Intake on the Pharmacokinetic of Single Dose SPH3127 Tablets in Chinese Health Subjects

Hypertension

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate (T8)

Rheumatoid Arthritis

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)

NMO Spectrum Disorder

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.

Advanced Solid Tumor

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer (B003-101)

HER2-positive Breast Cancer

China
Shanghai Bao Pharmaceuticals Co., Ltd.

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of KJ103 in Healthy Adults

Healthy

New Zealand
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Drug-drug Interaction Study of SPH3127

Drug Drug Interaction

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Not yet recruiting

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

Chronic Hepatitis B

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Recruiting

HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction

Heart Failure With Preserved Ejection Fraction

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Recruiting

A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy Subjects

Type 2 Diabetes

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Recruiting

Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration of HRS-5635 Injection in Chinese Healthy Subjects and the Safety, Tolerance, Pharmacokinetics and Antiviral Effect of Multiple Administration in Patients With Chronic Hepatitis B

Chronic Hepatitis B

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Active, not recruiting

A Phase Ⅲ Study of HR19006 Injection in Postsurgical Parenteral Nutrition

Parenteral Nutrition

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Completed

Study of HR20013 for Injection in Patients With Malignant Solid Tumors

Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy

China
Fujian Cosunter Pharmaceutical Co. Ltd

Unknown

Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of GST-HG131 Tablets

Hepatitis B

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Recruiting

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

Overweight or Obesity

China
Fujian Cosunter Pharmaceutical Co. Ltd

Recruiting

Phase I Study of GST-HG151 Tablets in Healthy Volunteers

Healthy Volunteers

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Active, not recruiting

Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

Type 2 Diabetes

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Active, not recruiting

Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

Overweight or Obesity

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Completed

A Relative Bioavailability Study of HRS9531 in Healthy Subjects

Type 2 Diabetes

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS3797 in Healthy Subjects

Skeletal Muscle Relaxation

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Completed

A Study of Remimazolam Tosilate for Sedation in the ICU

Sedation in the ICU

China
Fujian Cosunter Pharmaceutical Co. Ltd

Completed

Study on the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets

Hepatitis B

China
Fujian Cosunter Pharmaceutical Co. Ltd

Unknown

Study on the Tolerance and Pharmacokinetics of GST-HG141 Tablets (GST-HG141)

Hepatitis B

China
Fujian Cosunter Pharmaceutical Co. Ltd

Unknown

Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161

Solid Tumor | C-Met Mutation-Related Tumors

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Not yet recruiting

Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial

Acute Ischemic Stroke

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects

Overweight or Obesity; Type 2 Diabetes

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Recruiting

A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Patients With Candidemia and/or Invasive Candidiasis

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Not yet recruiting

A Trial of HRS-7450 in Chinese Healthy Volunteers

Cerebral Stroke
Fujian Shengdi Pharmaceutical Co., Ltd.

Not yet recruiting

Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

Overweight or Obesity

Clinical Trials Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations